The CXCL12/CXCR4 chemokine ligand/receptor axis controls (progenitor) cell homeostasis and trafficking. So far, an atheroprotective role of CXCL12/CXCR4 has only been implied through pharmacological intervention, in particular, because the somatic deletion of the CXCR4 gene in mice is embryonically lethal. Moreover, cell-specific effects of CXCR4 in the arterial wall and underlying mechanisms remain elusive, prompting us to investigate the relevance of CXCR4 in vascular cell types for atheroprotection.
T he chemokine receptor CXCR4 and its cognate ligand CXCL12 are best known for their role in the homing of progenitor cells to the bone marrow and their mobilization to the periphery. 1 Moreover, the importance of CXCR4 and CXCL12 in cell homeostasis, organ development, and vascularization explains why targeted disruption of either gene results in embryonic or perinatal lethality. [2] [3] [4] Stress-induced progenitor cell mobilization has been linked to a double-edged role of the CXCL12/CXCR4 axis after arterial injury. Whereas recruitment of angiogenic early outgrowth cells mediated by CXCL12/CXCR4 contributes to vascular regeneration, the mobilization of smooth muscle progenitor cells drives injury-induced neointima formation. 1, 5 However, CXCR4 is not only expressed on progenitor cells, but also on endothelial cells (ECs), vascular smooth muscle cells (SMCs), and diverse leukocyte subsets, all of which play a role in neointima formation and in native or diet-induced atherosclerosis. 1, 6 For instance, a protective role of endothelial CXCR4 promoting reendothelialization after endothelial denudation has been revealed during neointima formation. 7 In turn, an atheroprotective role of the CXCL12/CXCR4 axis has been related to the control of neutrophil numbers and activation, 8, 9 and microparticle-mediated recruitment of angiogenic cells, as well. 10 Given that somatic deletion of the CXCR4 gene in mice is embryonically lethal, the atheroprotective role of CXCR4 has so far been implied by relying on bone marrow chimeras or using pharmacological inhibitors, eg, systemic treatment with a CXCR4 antagonist. 8 Beyond that, vascular cell-specific effects of CXCR4 in the arterial wall and underlying mechanisms have not been elucidated in the context of atherosclerosis. Likewise, genome-wide association studies have validated significant associations between single nucleotide polymorphisms near CXCL12 as a lead gene in the 10q11 locus and the risk of coronary artery disease and early myocardial infarction, 11, 12 whereas a role of CXCR4 variants, in particular, those associated with cardiovascular risk beyond lipid levels, 13 remains unknown. Here, we examined the role of vascular CXCR4 in atherosclerosis by introducing an EC-specific and SMCspecific deficiency of Cxcr4 in a mouse model of dietinduced atherosclerosis, identified mechanisms underlying atherosclerosis-related effects of CXCR4 in these cell types, and analyzed the association of common CXCR4 variants with the risk for coronary heart disease (CHD), and CXCR4 expression in human atherosclerosis, as well.
METHODS
Please see the online-only Data Supplement for expanded methods.
Animals
All mice were on a C57/Bl6 background (online-only Data Supplement Table I ). For atherosclerosis studies, mice were fed a high-fat diet (HFD) containing 21% fat and 0.15% to 0.2% cholesterol (Altromin 132010, Sniff TD88137) for 12 weeks. All animal studies were approved by the local ethical committee.
Lesion Analysis and Intravital Microscopy
For analysis of atherosclerotic lesions, the aortic root and thoracoabdominal aorta were stained for lipid depositions with Oil Red O. Lesions in the root were quantified and averaged in 3 to 5 sections per mouse. Immunohistochemistry was performed to assess cellular composition. Leukocyte adhesion in carotid arteries was investigated by using intravital microscopy.
Clinical Perspective
What Is New?
• We show for the first time that the chemokine receptor CXCR4 in vascular cells limits atherosclerosis.
• Mechanistically, the CXCL12/CXCR4 chemokine ligand/receptor axis promotes endothelial barrier function through VE-cadherin expression and the stabilization of junctional VE-cadherin complexes.
• In arterial smooth muscle cells, CXCR4 sustains vascular reactivity responses and a contractile smooth muscle cell phenotype, whereas CXCR4 deficiency favors the occurrence of macrophage-like smooth muscle cells in atherosclerotic plaques and impairs cholesterol efflux.
• In humans, we identified a common allele variant within the CXCR4 locus to be associated with reduced CXCR4 expression in carotid artery plaques and increased risk for coronary heart disease.
What Are the Clinical Implications?
• Our data reveal that specifically enhancing the atheroprotective functions of arterial CXCR4 by selective modulators may open novel therapeutic options in atherosclerosis.
• Because systemic approaches to boost CXCR4 function carry a substantial risk of side effects and suboptimal efficacy, eg, due to proatherogenic effects of CXCR4-bearing hematopoietic cells, we envision a regional application of selectively targeted CXCR4 agonists or modulators through peri-or intravascular routes as a novel therapeutic option in atherosclerosis.
• Regional boosting of vascular CXCR4 may be accomplished using polymer-or nanoparticlebased delivery, as exemplified for microR-126-3p, which we previously showed to de-repress CXCR4 activity in endothelial cells.
In Vivo Permeability Assay
Endothelial permeability in the aortic arch was studied using Evans blue (1%, 30 minutes).
Cell Culture
Human aortic endothelial cells (hAoECs, Lonza), SV-40-transformed mouse endothelial cells, and human aortic vascular smooth muscle cells (hAoSMCs, Lonza) were used.
Small Interfering RNA Silencing and Gene Expression Analysis
Specific knock-down of β-catenin and CXCR4 (online-only Data Supplement Table II ) in hAoECs was accomplished by application of RNA interference technology (Qiagen). RNA was isolated using RNeasy kits and Tissuelyser (both Qiagen) and reverse transcribed using Moloney murine leukemia virus reverse transcriptase (Promega). Quantitative real-time polymerase chain reaction was performed using the Sybrgreen (online-only Data Supplement Table III) . Gene expression was normalized to GAPDH using the ΔΔCt method.
Transcription-Based Reporter Assay
WNT/β-catenin signaling activity was quantified in hAoECs by using a β-catenin-activated reporter system containing multimerized transcription factor/lymphoid enhancer-binding factor DNA-binding sites with inserted Gaussia luciferase as a reporter gene. Conditioned media were analyzed using the Gaussia luciferase assay kit (New England Biolabs) and a plate luminometer (Tecan).
In Vitro Permeability and Scratch Assay
An in vitro permeability assay (Millipore) was performed with hAoEC monolayers grown in 96-well cell culture inserts with a semipermeable membrane using fluorescein isothiocyanate-dextran. A scratch was introduced by dragging a sterile pipette tip across confluent hAoSMC monolayers to create a cell-free path, which was used for monitoring cell migration.
Vascular Reactivity
The thoracic aorta was divided into equal rings. Each aortic ring was connected to a force transducer in organ chambers using a passive tension of 2g for subsequent manipulation.
Analysis of CXCR4 in Humans
We examined the association of 345 common variants at the CXCR4 locus (±25 kB) in association with CHD by using data on altogether 92 516 CHD cases and 167 280 controls (see online-only Data Supplement Table IV for details of data sets included). Human carotid artery endarterectomy specimens (n=218) were collected in a cohort of patients undergoing vascular surgery, and utilization of human vascular tissues was approved by the Ethics Committee of the Medical Faculty at the TU Dresden (EK316122008). Quantification of CXCR4 mRNA expression and genotyping of rs2322864 in human specimens was performed and correlated with the clinical phenotype.
Statistical Analysis
All data are expressed as mean±SD or mean±standard error of the mean, as indicated. Statistical analyses were performed using GraphPad Prism 6 (GraphPad Software Inc 
RESULTS

CXCR4 on Arterial ECs Is Atheroprotective
To focus on EC-specific effects of CXCR4 in atherosclerosis-prone mice lacking the Apoe gene (Apoe -/-) and subjected to hyperlipidemia, Cxcr4-floxed (Cxcr4 fl/fl ) Apoe -/-mice were crossed with BmxCreER T2 -expressing mice (termed BmxCre), mediating efficient tamoxifeninducible Cxcr4 deletion in arterial ECs ( Figure 1A , online-only Data Supplement Figure IA) . 7 After 12 weeks of HFD, BmxCre + Cxcr4 fl/fl Apoe -/-mice displayed larger atherosclerotic lesions in the aortic root (Figure 1B through 1D) , the aortic arch ( Figure 1E ), and the aorta ( Figure 1F Figure 1M and 1N) .
The serum levels of CXCL12 (online-only Data Supplement Figure IH) 
CXCR4 on Arterial SMCs Is Atheroprotective
We next examined the contribution of CXCR4 in resident SMCs to atherosclerosis, crossing Table VI) , cholesterol and triglyceride serum levels were lower and body weight was slightly decreased in TaglnCre + Cxcr4 fl/fl Apoe -/-mice (online-only Data Supplement Table VI) .
As an alternative to constitutive SMC-specific Cxcr4 deletion, we studied atherosclerosis in SmmhcCre +
Cxcr4
fl/fl Apoe -/-mice ( Figure 2I ), enabling a tamoxifen-inducible Cxcr4 deletion in SMCs. 18 Whereas lesion size did not differ in the aortic root ( Figure 2J ), Table VII) . Furthermore, bone marrow (BM) reconstitution studies revealed that CXCR4 on BM-derived ECs does not affect atherosclerosis, whereas CXCR4 on a subset of BM-derived SMCs is proatherogenic (online-only Data Supplement Figure  III , online-only Data Supplement Tables VII and VIII). These effects are apparently unrelated to the function of CXCR4 in resident vascular cells.
Endothelial CXCR4 Reduces Vascular Permeability Through WNT/β-Catenin
To identify the processes underlying the atheroprotective functions of endothelial CXCR4, we examined its role in vascular permeability, which is crucially regulated by the EC layer, 19 also given that increased permeability is associated with enhanced atherosclerosis. 20 Histamineinduced vascular permeability was increased in C57/ Bl6 mice pretreated with the CXCR4 antagonist AMD3465 for 16 hours ( Figure 3A through 3C) , whereas systemic pretreatment with the CXCR4 ligand CXCL12 for 4 hours reduced histamine-induced vascular permeability ( Figure 3D ). Under conditions of HFD, vascular permeability was increased in Apoe -/-mice with an endothelial-specific Cxcr4 deficiency (Figure 3E Figure 3F and 3G). In vitro, the permeability of hAoECs, which express CXCR4 on their surface (online-only Data Supplement Figure  IVA) , to fluorescein isothiocyanate-dextran was increased by activation with the inflammatory cytokine tumor necrosis factor α (online-only Data Supplement Figure IVB ). In contrast, permeability was reduced by treatment of hAoECs with CXCL12 for 24 hours and even by short stimulation with CXCL12 for 15 minutes ( Figure 3H through 3J) . These effects were prevented by the CXCR4 antagonist AMD3100 ( Figure 3H through 3J), indicating that a CXCL12/CXCR4-mediated mechanism protects the EC barrier function. Likewise, blockade of Akt kinase signaling downstream of CXCR4 using SH5 prevented the reduction in endothelial permeability by CXCL12 ( Figure 3K ).
Because WNT signaling has been reported to reduce leakage of the blood-brain barrier 21 and β-catenin is present in endothelium covering human atherosclerotic lesions (online-only Data Supplement Figure IVC ), we examined a potential role for WNT/β-catenin in CXCL12-mediated protection of arterial endothelial barrier function using a luciferase reporter assay ( Figure 4A ). In hAoECs, CXCL12 induced a marked increase in WNT activity, which was inhibited by a CXCR4 antagonist, by small intervening RNAmediated CXCR4 knock-down or by endo-IWR1 as a specific WNT inhibitor ( Figure 4B , online-only Data Supplement Figure IVD) . Treatment of hAoECs with CXCL12 upregulated β-catenin transcript levels (online-only Data Supplement Figure IVE) . Likewise, CXCL12 increased both cytoplasmic and nuclear β-catenin protein levels, an effect blocked by silencing CXCR4 or by inhibiting WNT signaling with endo-IWR1 ( Figure 4C , online-only Data Supplement Figure IVF) . Accordingly, transcript expression of the WNT target genes MT1, cyclin-D1, and axin-2 was upregulated by CXCL12 (online-only Data Supplement Figure  IVG) . It is noteworthy that treatment with the WNT protein WNT3a, which triggers β-catenin stabilization by binding to the Frizzled receptor, or with the GSK3 inhibitor LiCl to stimulate WNT signaling reduced endothelial permeability ( Figure 4D ). The reduction of endothelial permeability induced by CXCL12 treatment for 24 hours or 15 minutes could be reversed by endo-IWR1 ( Figure 4E , online-only Data Supplement Figure  IVH) . Together, our data indicate that CXCL12 improves endothelial barrier function through the WNT pathway.
Endothelial CXCR4 Sustains VE-Cadherin Expression and Function
The adherens junctional protein VE-cadherin is an important contributor to endothelial barrier function. 19 Because CXCL12 regulates E-cadherin expression and localization in migrating epithelial cells, 22 we tested a role of VE-cadherin in the CXCL12/CXCR4-mediated control of endothelial permeability. In hAoECs, CXCL12 increased transcript and protein expression of VE-cadherin ( Figure 4F , online-only Data Supplement Figure  IVI ). This was paralleled by reduced protein levels of VE-cadherin in carotid artery lysates of BmxCre Figure 4G ). Of note, inhibiting WNT signaling with endo-IWR1 prevented the upregulation of VE-cadherin mRNA and protein levels by CXCL12 ( Figure 4F , online-only Data Supplement Figure IVI) , indicating that VE-cadherin expression is increased by the CXCL12/WNT pathway. The VE-cadherin-associated phosphatases SHP2, PTP1B, and VE-PTP are known to sustain VE-cadherin function and endothelial barrier integrity. 23, 24 Blocking SHP2 and PTPB1 prevented the reduction of endothelial permeability induced by CXCL12 or WNT3a ( Figure 4H ). Importantly, an increase in histamine-triggered vascular permeability on CXCR4 blockade could not be observed in engineered VE-PTP-FRB + /VE-cadherin-FKBP C57/Bl6 knock-in mice featuring a nondissociating, thus stabilized interaction between VE-cadherin and VE-PTP, which is induced by the chemical compound rapalog and has been previously linked to a preservation of the endothelial barrier 23 ( Figure 4I through 4K) . Together, our data show that the CXCL12/CXCR4 axis maintains endothelial integrity through the activity of VE-cadherin and VE-cadherin-regulating phosphatases. CXCL12/CXCR4 signaling did not alter the expression of other tight junctional proteins or inflammatory markers in ECs (data not shown). Finally, because vascular tone regulators such as endothelial nitric oxide synthase have been shown to influence atherogenesis 25 A, Experimental scheme. B, WNT activity in hAoECs as determined in a Gaussia luciferase WNT reporter assay, after stimulation with CXCL12 (100 ng/mL) for indicated periods. Cells were pretreated by the CXCR4 antagonist AMD3100 (1 µg/mL) or CXCR4 knock-down was performed using siRNA (CXCR4 kd). WNT activation was blocked by the WNT inhibitor endo-IWR1 (10 µmol/L) (n=3; 1-way ANOVA with the Sidak multiple comparisons test). C, β-Catenin protein levels in cytoplasmic and nuclear extracts of hAoECs after stimulation with CXCL12 (100 ng/mL) for 24 hours. Cells were pretreated with endo-IWR1 (10 µmol/L). Silencing of CXCR4 was performed using siRNA (CXCR4 kd). β-Catenin levels were normalized to cytoplasmic (tubulin) and nuclear (lamin β1) loading controls, respectively, and presented relative to untreated controls, as quantified by densitometry (n=3; 1-way ANOVA with the Tukey multiple comparisons test). A representative Western blot (left) and densitometry quantification (right) is shown. D, Permeability of hAoECs to FITC-dextran after stimulation with WNT3a (200 ng/mL) or the WNT activator LiCl (30 mmol/L) for 24 hours (n=5-10 wells from 4 independent experiments; Kruskal-Wallis test with the Dunn post test). E, Permeability of hAoECs to FITC-dextran after stimulation with WNT3a (200 ng/mL) or CXCL12 (100 ng/mL) for 24 hours and pretreatment with endo-IWR1 (1 µmol/L) for 1 hour, as indicated (n=7-9 wells from 3 independent experiments; 1-way ANOVA with the Tukey multiple comparisons test). F, VE-cadherin protein levels in cytoplasmic extracts of hAoECs after stimulation with CXCL12 (100 ng/mL) for 24 hours and treatment with endo-IWR1 (10 µmol/L), as indicated. Knock-down of CXCR4 was performed using siRNA (CXCR4 kd). VE-cadherin expression was normalized to tubulin and presented relative to untreated, as quantified by densitometry (n=3; 1-way ANOVA with the Tukey multiple comparisons test). A representative Western blot and densitometry quantification is shown. Controls received control siRNA (B, C, and F) 
CXCR4 on SMCs Regulates Lesional Cholesterol Efflux
Cholesterol efflux capacity has been independently and inversely associated with atherosclerotic cardiovascular disease in patients with familial hypercholesterolemia. 26 Analysis of cholesterol efflux revealed a reduction in efflux capacity from lipid-laden macrophages when using serum from TaglnCre + versus TaglnCre  -Cxcr4 fl/ fl Apoe -/-mice on HFD as acceptor. Such reduced cholesterol efflux was observed without and with cAMP stimulation, which enhances cellular lipid efflux to the apolipoprotein acceptor ApoA-1 ( Figure 5A ). 
CXCR4 on SMCs Supports NO-Dependent Vascular Reactivity
Because SMCs are crucial in regulating vascular tone, we examined the effects of SMC-specific Cxcr4 deficiency on blood pressure and on vascular contraction and relaxation in organ baths. Systolic and diastolic blood pressure did not differ between TaglnCre + versus TaglnCre 
CXCR4 Maintains SMCs in a Contractile Phenotype
Vascular SMCs display a significant plasticity and can dedifferentiate from a contractile phenotype to a more synthetic phenotype. This SMC phenotype switching has recently been implicated in influencing atherosclerosis. 28 We found that mice with SMC-specific Cxcr4 deficiency showed an increased aortic expression of vimentin, a synthetic marker induced by platelet-derived growth factor BB, 29 and of CD248 (endosialin), which is involved in platelet-derived growth factor-mediated cellular effects and associated with a synthetic SMC phenotype ( Figure 5G , online-only Data Supplement Figure VR and VS). 30, 31 Moreover, staining for vimentin, CD248, CD68, and lipids (Nile red) revealed a higher prevalence of dedifferentiated SMCs in plaque caps of these mice ( Figure 5H ). In vitro, both WNT3a and CXCL12 increased the expression of contractile markers (Tagln, smoothelin, CNN1) in cultured hAoSMCs, whereas the expression of synthetic markers was reduced (for CD248 after WNT3A treatment, Figure 5I , online-only Data Supplement Figure VT) or not altered (after CXCL12 treatment, Figure 5J , online-only Data Supplement Figure VU) , respectively. Combined with our finding that the CXCL12/CXCR4 axis drives WNT activation ( Figure 4B ), these data reveal that the CXCL12/CXCR4/ WNT axis supports a contractile phenotype in SMCs.
CXCR4 Risk Variants Are Associated With Impaired CXCR4 Expression
We evaluated the relevance of our findings indicating a protective role of CXCR4 to human atherosclerosis. Immunohistochemistry in carotid endarterectomy specimen detected CXCR4 protein expression in both ECs and SMCs of human atherosclerotic lesions ( Figure 6A) , and the presence of active β-catenin indicating an activation of the WNT pathway, as well ( Figure 6B ). We next examined the association of all common variants at the CXCR4 locus with coronary heart disease (CHD) using data on altogether 92 516 CHD cases and 167 280 controls (including CARDIoGRAMplusC4D [Coronary Artery Disease Genome Wide Replication and Metaanalysis Plus the Coronary Artery Disease Genetics]) and fine mapping of data from the 1000 Genomes Project (see online-only Data Supplement Table IX for details of data sets included). Thus, we identified the C-allele at rs2322864 (minor allele frequency 26%) to be significantly associated with increased CHD risk (odds ratio, 1.04 for every C-allele; P=4.38×10 -7 ) ( Figure 6C ) and with reduced CXCR4 gene expression in wholeblood on expressive quantitative trait loci analysis (data not shown). It is noteworthy the C/C-genotype at rs2322864 was found to be linked to reduced CXCR4 mRNA expression in atherosclerotic plaques of human carotid arteries ( Figure 6D ). Moreover, CXCR4 expression was lower in patients with symptomatic versus asymptomatic carotid stenosis, as evident by neurological events, eg, transient ischemic attacks (Figure 6E) , consistent with the notion that low vascular CXCR4 levels give rise to increased risk for carotid and coronary atherosclerosis.
DISCUSSION
Our data unequivocally reveal that CXCR4 is atheroprotective in vascular cells by sustaining endothelial integrity and promoting the contractile phenotype of SMCs. This conclusion is supported by the increase in atherosclerosis on arterial EC or SMCspecific deletion of Cxcr4 in mice, and reduced CXCR4 expression in human carriers of a common CXCR4 risk variant for CHD, as well. Our results corroborate and extend the importance of CXCR4 in atherosclerosis and human disease beyond previous findings using its systemic blockade or disruption in bone marrow, and its role in stem and cancer cell migration, as well.
Sustained endothelial integrity on CXCL12/CXCR4 signaling was mediated by (1) Akt/WNT signaling, (2) ORIGINAL RESEARCH ARTICLE involved the VE-cadherin-associating phosphatases VE-PTP, SHP2, and PTP1B, 23, [32] [33] [34] and was linked with (3) increased VE-cadherin expression and function, as evidenced by reinforced interactions of VE-cadherin and VE-PTP to conserve endothelial barrier function. 23 As a result, interference with the CXCL12/CXCR4 axis enhanced Evans blue extravasation into the vascular wall under conditions of acute inflammation and during atherogenesis in vivo. Moreover, endothelial Cxcr4 deficiency was associated with an upregulation of intercellular adhesion molecule-1 expression in arterial ECs covering atherosclerotic lesions, reflecting their activation, and promoting atherogenic leukocyte recruitment and increased macrophage content in the lesions. The We examined the association of 345 common variants at the CXCR4 locus (±25 kB) with CHD by using data on 92 516 CHD cases and 167 280 controls (see online-only Data Supplement Table IV for details of data sets included), most notably interrogating the CARDIoGRAMplusC4D data. We conducted fine-mapping studies in 12 500 myocardial infarction cases and 12 000 controls and genotyped all 512 variants with a minor allele frequency >0.1% identified by the 1000 Genomes Project at the CXCR4 locus. A P value of 5×10 -5 was considered as statistically significant based on Bonferroni correction for 857 variants. Odds ratios (OR) with 95% confidence intervals (CIs) and P values are given. The C-allele at rs2322864 was found to be associated with increased CHD risk (OR, 1.04; P=4.38×10 -7 ). D, Association of rs2322864 with CXCR4 expression in carotid endarterectomy specimen (C/T; T/T: n=121 and C/C: n=67, Mann-Whitney test with Bonferroni correction to adjust for multiple comparisons). E, Correlation of CXCR4 expression with clinical carotid stenosis, as evident by neurological events, eg, transient ischemic attacks (A, asymptomatic, n=25; S, symptomatic, n=19, unpaired t test with Welch correction); CXCR4 expression was normalized to β-actin expression (mean±SEM). *P<0.05. CHD indicates coronary heart disease; EC, endothelial cell; SEM, standard error of the mean; SMA, smooth muscle actin; and SMC, smooth muscle cell.
latter effect was not attributable to a direct effect of the CXCL12/CXCR4 axis on the expression of inflammatory mediators and adhesion molecules in ECs, because it could not be stimulated or modulated by CXCL12 in vitro. This implies that the marked leukocyte trafficking into early lesions of mice lacking endothelial Cxcr4 was rather related to disturbed endothelial integrity and increased permeability, subsequently enhancing vascular inflammation and adhesion molecule expression on the endothelium.
WNT activation was previously found to decrease leakage of the blood-brain barrier, 21 implicating β-catenin transcriptional activity in reduced permeability of brain ECs. 35 A link between CXCL12 and WNT has been suggested in peripheral nerve sheath tumors and pancreatic β-cells, triggering cell growth and survival, respectively. 36, 37 We found that the CXCL12/CXCR4 axis reduces endothelial permeability through Akt/ WNT-and VE-cadherin-mediated mechanisms, which may refine and underlie findings that CXCL12 or its analogs can reduce thrombin-induced endothelial permeability and pulmonary vascular leakage in a model of lipopolysaccharide-induced acute respiratory distress syndrome. 38, 39 Notably extending previous findings, 23 stabilizing the interaction between VE-cadherin and VE-PTP prevented the impairment of endothelial barrier function on interference with CXCR4. Surprisingly, atherosclerosis-prone endothelium displays increased β-catenin nuclear localization. 40 However, enhancing WNT signaling by blocking the endogenous β-catenin/ WNT inhibitor GSK3 reduced atherosclerosis and inflammatory endothelial VCAM-1 expression, 41 further supporting an atheroprotective role of WNT, at least in part, at the endothelial level. Findings that endothelial KLF4 is itself a β-catenin target gene, 42 drives VEcadherin expression 43 and is atheroprotective in ECs, 44 may provide additional evidence for a downstream link of CXCL12-induced β-catenin and VE-cadherin expression. Given the involvement of SHP2 in Akt signaling, 45 our data unveil that the CXCL12-CXCR4 axis can sustain endothelial integrity through (1) SHP2/Akt/WNT signaling inducing VE-cadherin expression, and (2) VE-cadherin-associated phosphatases, namely, VE-PTP, supporting VE-cadherin stability and function.
In the second line of investigation, we show that the CXCL12/CXCR4 axis also favors a contractile over a synthetic phenotype in arterial SMCs to explain increased lesion formation in mice with SMC-specific Cxcr4 deficiency. Phenotype switching of contractile SMCs to a synthetic phenotype has long been considered to contribute to atherogenesis by generating a more inflammatory SMC phenotype. 28 A recent study supported this notion by documenting that loss of myocardin, a promotor of the contractile and noninflammatory SMC phenotype, increased atherosclerosis. 46 Here, we uncover a role for a chemokine ligand/receptor axis in influencing SMC phenotype in the context of atherosclerosis. In addition to upregulating markers (vimentin and endosialin) associated with the synthetic SMC phenotype, [29] [30] [31] SMC Cxcr4 deficiency increasingly switched SMCs in atherosclerotic lesions to a macrophage-like phenotype featuring costaining for CD68 and Nile red. Such SMC-derived macrophage-like cells have only recently been identified in atherosclerotic lesions, and are suggested to augment atherosclerosis. 28, 47, 48 Likewise, endosialin has been found to promote atherosclerosis through phenotypic remodeling of vascular SMCs. 31 In accord with CXCL12 driving WNT signaling, we confirmed that both CXCL12 and WNT3a promoted the contractile phenotype of SMCs in vitro, 49 consistent with our observations on Cxcr4 deficiency in vivo. Combined with a reduced macrophage cholesterol efflux capacity attributable to lower ApoA1 serum levels, this may underlie atherogenic effects of Cxcr4 deficiency in SMCs. It is notable that because an autocrine loop for CXCR4-dependent expression of CXCL12 has been established in ECs, 10 a cross talk of CXCR4-bearing SMCs and ECs via CXCL12 in the arterial wall may also contribute to atheroprotection. Proatherogenic effects of CXCR4 in BM-derived SMCs contrasted a protective role in resident SMCs, likely because of differential expression levels or functions depending on the cellular context and origin.
Genome-wide association studies have validated highly significant associations of variants near CXCL12 as a lead gene in the 10q11 locus with the risk for CAD and myocardial infarction. 11, 12 Based on a more recent analysis, we have now extended the role of CXCL12 to the locus of its receptor CXCR4, showing that a common variant, the C-allele at rs2322864 was associated with increased risk for CHD, and the C/C-genotype was associated with reduced CXCR4 expression in whole blood and carotid atherosclerotic plaques. Of note, the odds ratio for CHD risk appeared to be more prominent in predominantly female cohorts. CXCR4 expression was also reduced in patients with symptomatic in comparison with asymptomatic carotid atherosclerosis, indicative of a more unstable plaque phenotype. Collectively, our data substantiate the protective role of the CXCL12/CXCR4 axis in cells of the arterial wall. Because global inducible Cxcr4 deficiency less markedly exacerbates atherosclerosis (D. Saleheen et al, unpublished data, 2017 ), CXCR4 may also confer proatherogenic effects in other cell types distinct from neutrophils, ECs, or SMCs; however, the identity of this cell type, eg, in the hematopoietic or other nonvascular cell compartments, remains to be elucidated. Our data linking variants in the CXCR4 gene locus with CHD risk support the notion that CXCR4 is a disease-modifying receptor in atherosclerosis, indicating that protective effects may prevail, but cannot explain differences or resolve the ORIGINAL RESEARCH ARTICLE directionality in BM-related versus peripheral effects of CXCR4 on atherogenesis.
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